Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06276010
Recruiting Not applicable

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

NCT06276010 · tracked via the Priya Life Science China tracker
Sponsor
Xiaotong Hou
Phase
Not applicable
Started
2024-07-01
Last updated
2025-09-25

Condition(s) studied

Extracorporeal Membrane Oxygenation Complication

Investigational drug(s) / intervention(s)

nafamostat mesilateunfractionated heparin group

nafamostat mesilate: Use nafamostat mesilate as an anticoagulant

unfractionated heparin group: Use unfractionated heparin as an anticoagulant

Study summary

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years old 2. VA-ECMO or VV-ECMO was accepted after cardiac surgery. 3. The ECMO treatment team believes that systemic anticoagulation is needed 4. Sign the informed consent form Exclusion Criteria: 1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study. 2. Long-term use of anticoagulants before establishment of ECMO 3. Antiplatelet drugs were used before the establishment of ECMO 4. Severe liver insufficiency 5. Connective tissue disease 6. There is a history of allergy to heparin or nemolastat mesylate. 7. Pregnant 8. Previous diagnosis of heparin-induced thrombocytopenia 9. Expect to die within 48 hours 10. ECPR

Primary outcome measure(s)

  • Incidence of thrombotic complications — Within 7 days after starting anticoagulant therapy
    Thrombotic events include loop thrombosis, oxygenator thrombosis, venous thromboembolism, arterial thromboembolism, and cerebral infarction.

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital Beijing Beijing Municipality Recruiting

More Xiaotong Hou trials in China

Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients Recruiting
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation Recruiting

Other trials for the same condition

Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock Recruiting
PK/PD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment Starting soon
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06276010 on ClinicalTrials.gov ↗ ← All trials in China